A mouse feeding study from Washington State University looking at whether dietary goji berry changes the course of chemically induced colitis.
How the study was done
Six-week-old male C57BL/6 mice were fed a standard AIN-93G diet with or without 1% (w/w) goji berry for four weeks. Colitis was then induced with 3% dextran sulfate sodium in drinking water for 7 days, followed by a 7-day remission period.
What it found
Goji supplementation reduced body weight loss, diarrhoea and gross bleeding, lowered the disease activity index and reduced colon shortening. The 30% mortality seen in the untreated colitis group was avoided. Histologically it reduced colonic oedema, mucosal damage and neutrophil infiltration, alongside lower expression of CXCL1, MCP-1, IL-6 and COX-2.
Limitations worth stating
A mouse model using a chemical colitis inducer, at 1% of total diet — a substantial intake relative to normal human consumption. Nothing here has been shown in people.
Why this matters when sourcing goji berries
Relevant mainly as background if a customer is developing a gut-health or anti-inflammatory positioning: it tells you the research base is preclinical. That is worth knowing before marketing copy gets written, because most jurisdictions will not accept an animal study as support for a consumer-facing claim.
Source
Kang Y, Xue Y, Du M, Zhu MJ. Journal of Nutritional Biochemistry, 2016 — read the original paper.
Research summary. This page summarises independently published research on Lycium barbarum for reference. It is not a health claim and not a statement about any product we supply. Union-Sure supplies goji berries as a food ingredient; we make no medical or therapeutic claims.
